Posts Tagged: drug prices
Price Controls and Compulsory Licensing Reduce Patient’s Healthcare Options
Once we go down a path of government price controls and compulsory licensing we will have foregone opportunities for other, more rational policy choices and will soon …
Reflections on Drug Patents and the High Cost of Healthcare
The Hatch-Waxman Act and the Biologic Price Competition and Innovation Act are both forged from a noble ideal, grounded in a commitment to a robust and earnest …
Drug-Patent Abuse and the High Cost of Healthcare: Case of the Double-Half Dose-Time Injection
Ever since the Supreme Court decided KSR v. Teleflex, it has been appropriate to reject a patent claim because it was obvious to try. If twice the …
To Make Healthcare More Affordable, Fight Drug Patent Abuse with a Fury
If a drug company plants a more than 100-patent thicket to protect market exclusivity, then it had better be able to justify why it should deserve the …
A Fleeting Glimpse of Reason in the Drug Development Debate
Despite the difficulties, the private sector is far and away the best bet for developing the desperately needed medicines of the future. Government is a critical partner …
Focus on Stronger IP Incentives: Price Setting is Not the Cure for Healthcare Spending
The WHO is gathering governments, academics and activists in Amsterdam next month to discuss price setting options for medicines. But the so-called Fair Pricing Forum ignores the …
Will President Trump directly negotiate Medicare prescription drug pricing?
The savings impact of directly negotiated drug costs is considered negligible, but intrusion into biomedical pricing will destabilize life science commercialization... Any way you slice it, added …
Winning the Drug Development Debate
We create two new companies around academic inventions every day of the year. The critical role such companies play in drug development is clear. The successful integration …
The EpiPen Episode’s Silver Lining
EpiPen's eruptive timing was important. Had Congress been in town, lawmakers would have filled the front pages with populist blather. Had Mylan been less forthcoming about the …
Government is to blame for the skyrocketing price of EpiPens, not patents
The problem is that the government is standing in the way of these competitive autoinjectors getting into the hands of the patients who need them. For example, …
Counterfeit Medicines and the Role of IP in Patient Safety
Given the devastating impact of counterfeit medicines on patients and the importance of intellectual property protection in combating pharmaceutical counterfeiting, it is troubling that the UN High …
A Simple Way to Lower Drug Prices
Consumers suffer the scourge of high drug prices. Brand-name drug companies reap monopoly profits. But generic drugs, which promise lower prices, are often nowhere to be found. …
Bayh-Dole Under March-in Assault: Can It Hold Out?
The new year was hardly underway before Representative Lloyd Doggett (D-TX) and 50 of his House colleagues sent a letter to Health and Human Services Secretary Sylvia Burwell …
Legal Threats to Strong Returns on Pharmaceutical Patents Grow, Threatening Innovation
Pharmaceuticals is the industry sector where a strong patent system, promising substantial returns to successful innovation, is of paramount importance. Regrettably, the weakening of pharmaceutical patent rights …
Will More Regulation Create Cheaper Drugs?
The idea of reducing drug prices through more government control is always simmering on the backburner and doesn’t require much to bring it to a full …
